Replimune Group, Inc. is a clinical-stage biotechnology company focused on the development of oncolytic immunotherapies to treat cancer. The company's lead product candidate, RP1, is a selectively replicating version of herpes simplex virus 1 (HSV-1) that is designed to infect and destroy cancer cells. RP1 is currently being evaluated in multiple clinical trials for the treatment of various solid tumors. Replimune is also developing a pipeline of other oncolytic immunotherapies, including RP2, RP3, and RP-Abl, which are designed to target different types of cancer. The company was founded in 2015 and is headquartered in Cambridge, Massachusetts.
Highest paying job titles at Replimune Group, Inc. include Director, Quality Control, Director, Accounts Payable, and Senior Quality Assurance Engineer